eviQ Survey on Assessment of Kidney Function in Cancer Patients and Utilisation in Dose Adjustment in Kidney Dysfunction - post ADDIKD implementation - Oct 2024 |
*Complete the survey for your chance to win one of four $50 gift cards*
Background
The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) was developed and published on the eviQ website in October 2022. The guideline was developed to provide a consensus-based standardised approach to the assessment of kidney function in cancer patients and clinically driven recommendations on dose adjustment for anticancer drugs in kidney dysfunction.
The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) was developed and published on the eviQ website in October 2022. The guideline was developed to provide a consensus-based standardised approach to the assessment of kidney function in cancer patients and clinically driven recommendations on dose adjustment for anticancer drugs in kidney dysfunction.
Starting in July 2023, eviQ proceeded to implement the ADDIKD guideline recommendations into 700+ eviQ drug treatment protocols. This was completed in June 2024.
Why are we undertaking this survey?
The following questions are intended to gain an understanding of the impact of the ADDIKD guideline and the implementation of its recommendations into eviQ drug treatment protocols on clinician practice and cancer centres.
Completion of this survey is voluntary and anonymous (unless you enter the competition to win one of four $50 gift cards) and should take approximately 15 minutes.